About a year ago, patients in a clinical trial of a Merck Alzheimer’s drug called Verubecestat received a phone call from their memory clinics.  “Stop taking the pills and return those left to the clinic immediately,” they were told. “The trial has been cancelled.”  My wife and about 1,500 Alzheimer’s patients around the world returned the…